Society for Surgery of the Alimentary Tract Annual Meeting

Back to SSAT Site
Annual Meeting
  Program and Abstracts
  Ticketed & Highlighted Sessions
  Past & Future Meetings
  Photo Gallery
  Past DDW on Demand
Winter Course
Other Meetings of Interest

Back to 2018 Program and Abstracts

Tossapol Kerdsirichairat*1, Marcia I. Canto1, Madeline Ford1, Michael G. Goggins1, Amanda Blackford3, Toshiya Abe1, Ralph Hruban2, Anne Marie Lennon1, Alison Klein3, Ihab R. Kamel4, Elliot K. Fishman4, Matthew J. Weiss5, Charles J. Yeo5, Richard D. Schulick6, Christopher L. Wolfgang5
1Gastroenterology/Medicine, Johns Hopkins University, Baltimore, MD; 2Pathology, Johns Hopkins University, Baltimore, MD; 3Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, MD; 4Radiology, Johns Hopkins University, Baltimore, MD; 5Surgery, Thomas Jefferson University, Philadelphia, PA; 6Gastroenterology/Medicine, University of Colorado, Denver, CO

Screening high-risk individuals (HRI) for pancreatic adenocarcinoma (PDAC) and its precursors is a potential approach to improving survival. However, little is known about the outcomes after pancreatic resection for screening-detected pancreatic lesions. We report postoperative surgical and patient-centered outcomes. METHODS: HRI enrolled in prospective CAPS surveillance studies (1998-2017) consisted of relatives from familial PC kindreds, those with Peutz-Jeghers syndrome, germline BRCA1/2 mutations, PALB2, p16/CDKN2A, ATM, or Lynch syndrome. Those who had surgery for pancreatic lesions detected by EUS/MRI/CT and >6 months follow-up were included in this analysis. Surgical outcomes (mortality, morbidity, length of stay, readmission, diabetes), patient-outcomes (pain, patient satisfaction (Likert scale of 1 completely satisfied to 7 completely dissatisfied), pre- and post-operative health-related quality of life (QoL, Short Form 36) were assessed. Survival was estimated using Kaplan-Meier analysis. RESULTS: Among 354 HRI with continued surveillance, 46 (13%) asymptomatic HRI had surgery for suspected pancreatic neoplasms. 10/11 (91%) screening-detected PDACs were resectable (all R0) (by comparison rates of resection of PDAC in the US are ~20%) with 2(18%) Stage IA (18%), 2(18%) Stage IIA, 6(54%) Stage IIB, and 1(9%) Stage IV(Table 1). 40 HRI had partial resection, then 8 of these underwent completion pancreatectomy at median 3.81 years (IQR 2.5-7.6) for a new lesion. 2/8 (25%) of the HRI with partial resection developed PDAC in the remnant pancreas. Postoperative complications developed in 15 HRI (32.6%): delayed gastric emptying (6 Whipple (W), 1 distal pancreatectomy (DP), 2 total pancreatectomy (TP)), surgical site infection (2 W, 2 DP), grade B pancreatic fistula (2 W, 2 DP) and cholangitis (2 W, 1 DP). There were no 90-day perioperative deaths or hemorrhage. Median length of stay was 7 days (IQR 5-11), with 3 30-day readmissions. Diabetes developed in 6/28 HRI with no prior diabetes after partial resections. 11(24%) use an insulin pump, with 2 ER visits (1 admission in a post TP patient) related to hypo/hyperglycemia. Median follow-up was 7.3 years, IQR 4.2-9.9). There were 8 deaths, 5 related to PDAC (10.9%). 3-year and 5-year overall survival were 97.7% and 88.2%, respectively. Preoperative and postoperative median physical component scores (90 vs. 95, respectively, p=0.44) and mental component scores (84 vs 88, respectively,0.81) were comparable. Median postoperative bodily pain score was 90, (baseline 90, p=0.32). Median post-operative patient satisfaction was 2 (IQR 2-3). CONCLUSION: Screening HRI leads to detection of PDAC, improved resectability, and stage shift compared to known national rates. Surgical resection is associated with acceptable morbidity and no mortality in this series. Patient satisfaction is high and QoL is preserved.

Table 1: Characteristics of 46 HRI and Screening-Detected Lesions, Stratified by Highest Grade of Pathologic Diagnoses
Pathology (n)Indication for Surgery (n)Median Age (years)/
% Male
Type of Operations
(Number of Open/
Minimally Invasive)
Median Tumor Size (cm)AJCC Stage for PDACMedian Follow-Up (years)/
% Alive
3-Year Survival/
5 year-Survival
Cause of Death, where applicable (n)
PDAC (11)Mass (8)
Cyst with duct dilatation (1)
Rapid cyst growth (2)
Whipple (6/0 )
Distal (4/0)
Total (1/0)
(IQR 1.5-3.5)
Stage IA, T1N0M0 (2)
Stage IIA T3N0M0 (2)
Stage IIB, T2N1M0 (4)
Stage IIB, T3N1M0 (2)
Stage IV, T3N1M1 after remote Whipple for IPMN-LGD (1)
non-PDAC related(1)
High-grade PDAC precursors (10)        
PanIN-3 (7)Cyst with duct dilatation (3)
Rapid cyst growth (4)
Whipple (3/0)
Distal (2/0)
Total (2/0)
(IQR 0.9-1.5)
Tis7.6/85.7%100%/100%Non-PDAC related (1) at 7 years
IPMN HGD (6)Mass (1)
Cyst with mural nodule (1)
Cyst with duct dilatation (1) Rapid cyst growth (3)
Whipple (2/0)
Distal (3/1)
(IQR 1.0-2.3)
Tis7.4/100%100%/100%No death
Low-grade PDAC precursors: PanIN2, IPMN-LGD, IPMN-MGD (25)Mass (11)
Cyst with duct dilatation (4)
Rapid cyst growth (10)
Whipple (5/1)
Distal (12/4)
Total (2/1)
(IQR 0.7-2.2)
NA8.4/96%100%/100%Non-PDAC related (1) at 11.2 years

Figure 1: Survival of high risk individuals (HRI) after pancreatic resection using Kaplan-Meier's method and compared using the log-rank test. Comparing to those with pancreatic ductal adenocarcinoma (orange), those with high-grade dysplastic precursors (blue) had comparable survival (p=0.14) and those with other low-grade dysplastic precursors (purple) had better overall survival (p=0.02).

Back to 2018 Program and Abstracts

© 2019 Society for Surgery of the Alimentary Tract. All Rights Reserved. Read the Privacy Policy.